These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 26238672

  • 1. Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.
    Combe B, Furst DE, Keystone EC, van der Heijde D, Luijtens K, Ionescu L, Goel N, Emery P.
    Arthritis Care Res (Hoboken); 2016 Mar; 68(3):299-307. PubMed ID: 26238672
    [Abstract] [Full Text] [Related]

  • 2. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [Abstract] [Full Text] [Related]

  • 3. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T.
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [Abstract] [Full Text] [Related]

  • 4. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
    Kang YM, Park YE, Park W, Choe JY, Cho CS, Shim SC, Bae SC, Suh CH, Cha HS, Koh EM, Song YW, Yoo B, Lee SS, Park MC, Lee SH, Arendt C, Koetse W, Lee SK.
    Korean J Intern Med; 2018 Nov; 33(6):1224-1233. PubMed ID: 29294598
    [Abstract] [Full Text] [Related]

  • 5. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS, van Vollenhoven R, Kavanaugh A, Strand V, Vencovsky J, Schiff M, Landewé R, Haraoui B, Arendt C, Mountian I, Carter D, van der Heijde D.
    Arthritis Res Ther; 2015 Sep 10; 17(1):245. PubMed ID: 26353833
    [Abstract] [Full Text] [Related]

  • 6. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
    Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T.
    Ann Rheum Dis; 2017 Aug 10; 76(8):1348-1356. PubMed ID: 28153828
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.
    Bi L, Li Y, He L, Xu H, Jiang Z, Wang Y, Li X, Wei W, Gu J, Wang G, Zhang Z, Zhou B, Liu Y, Wu Z, Liu H, He D, Lv Z, Li Z, Zuo X, Dong L, Wu H, Zhang H, Chen H, Bao C, Zhang Z, Zhang M, Song H, Zheng Y, Jiang L, Liu X, Boehnlein M, Dunkel J, Shao J, Harris K, Li Z.
    Clin Exp Rheumatol; 2019 Aug 10; 37(2):227-234. PubMed ID: 30183595
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 10; 24(5):715-24. PubMed ID: 24313916
    [Abstract] [Full Text] [Related]

  • 9. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME, Fleischmann R, van Vollenhoven RF, Emery P, Huizinga TW, Cutolo M, van der Heijde D, Duncan B, Davies O, Luijtens K, Dougados M.
    Arthritis Res Ther; 2015 Nov 15; 17():325. PubMed ID: 26568428
    [Abstract] [Full Text] [Related]

  • 10. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.
    Weinblatt ME, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P.
    Arthritis Rheumatol; 2017 Oct 15; 69(10):1937-1948. PubMed ID: 28666080
    [Abstract] [Full Text] [Related]

  • 11. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
    Tanaka Y, Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Int J Rheum Dis; 2020 Mar 15; 23(3):316-324. PubMed ID: 31957303
    [Abstract] [Full Text] [Related]

  • 12. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.
    Rheumatol Int; 2017 Sep 15; 37(9):1441-1452. PubMed ID: 28523420
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Jul 15; 24(4):552-60. PubMed ID: 24981319
    [Abstract] [Full Text] [Related]

  • 14. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Keystone E, Heijde Dv, Mason D, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K.
    Arthritis Rheum; 2008 Nov 15; 58(11):3319-29. PubMed ID: 18975346
    [Abstract] [Full Text] [Related]

  • 15. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis.
    Furst DE, Shaikh SA, Greenwald M, Bennett B, Davies O, Luijtens K, Staelens F, Koetse W, Bertin P.
    Arthritis Care Res (Hoboken); 2015 Feb 15; 67(2):151-60. PubMed ID: 25302624
    [Abstract] [Full Text] [Related]

  • 16. Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial.
    Pfeil A, Nussbaum A, Renz DM, Hoffmann T, Malich A, Franz M, Oelzner P, Wolf G, Böttcher J.
    Arthritis Res Ther; 2020 Oct 06; 22(1):229. PubMed ID: 33023661
    [Abstract] [Full Text] [Related]

  • 17. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Bernal JA.
    Cochrane Database Syst Rev; 2017 Sep 08; 9(9):CD007649. PubMed ID: 28884785
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
    Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P, Shaughnessy L, VanLunen B, van der Heijde D.
    Ann Rheum Dis; 2014 Dec 08; 73(12):2094-100. PubMed ID: 23918037
    [Abstract] [Full Text] [Related]

  • 19. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R.
    Lancet; 2016 Dec 03; 388(10061):2763-2774. PubMed ID: 27863807
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
    Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 03; 24(5):734-43. PubMed ID: 24593170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.